What's the best biologic for RA lung disease?

Rheumatoid arthritis patients with interstitial lung disease (ILD) have better long-term survival when given rituximab as first-line treatment instead of a TNF inhibitor, new research shows.

Patients on rituximab were around half as likely to have died within five years compared with TNF inhibition, UK researchers reported at the 2016 American College of Rheumatology/ARHP meeting in Washington.

Rheumatology bodies have long